Brought to you by

Merck acquires GlycoFi for $400mm
25 Feb 2011
Executive Summary
Impressed with results of a collaboration formed by the parties last year, Merck has decided to acquire glycoprotein therapeutics developer GlycoFi for $400mm cash, gaining access to technology to develop biosimilars.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com